PT - JOURNAL ARTICLE AU - Ata Ur Rehman Maaz AU - Jim O’Doherty AU - Mehdi Djekidel TI - <sup>68</sup>Ga-DOTATATE PET/CT for Neuroblastoma Staging: Utility for Clinical Use AID - 10.2967/jnmt.120.258939 DP - 2021 Sep 01 TA - Journal of Nuclear Medicine Technology PG - 265--268 VI - 49 IP - 3 4099 - http://tech.snmjournals.org/content/49/3/265.short 4100 - http://tech.snmjournals.org/content/49/3/265.full SO - J. Nucl. Med. Technol.2021 Sep 01; 49 AB - Metaiodobenzylguanidine (MIBG) imaging has been the standard for neuroblastoma staging for many decades. Novel agents such as 18F-DOPA and 68Ga-DOTATATE are being used nowadays in academic centers. During the coronavirus disease 2019 (COVID-19) pandemic, procurement of 123I-MIBG has proved particularly challenging, necessitating the use of 68Ga-DOTATATE PET. 68Ga-DOTATATE is Food and Drug Administration–approved for imaging of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors. Methods: 68Ga-DOTATATE PET/CT imaging was performed for staging of 3 pediatric patients with neuroblastoma at our institution. A review of the literature was also completed. Results: 68Ga-DOTATATE PET/CT scans were successfully performed on all patients. All patients showed 68Ga-DOTATATE–avid disease. PET scans showed an excellent spatial resolution and demonstrated high accuracy in concordance with current European Association of Nuclear Medicine guidelines. Conclusion: We have presented 68Ga-DOTATATE PET/CT imaging for staging of neuroblastoma and believe it can reliably be used as an alternative to 123I-MIBG. It has technical, clinical, and practical advantages making it an attractive option. Further multicenter studies are required before it can be recommended for standard clinical use.